Nchi: Uingereza
Lugha: Kiingereza
Chanzo: MHRA (Medicines & Healthcare Products Regulatory Agency)
Sucralfate
Chugai Pharma UK Ltd
A02BX02
Sucralfate
1gram
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 01030300; GTIN: 5060069010018
OBJECT 1 ANTEPSIN TABLETS 1G Summary of Product Characteristics Updated 23-Oct-2013 | Chugai Pharma UK Limited 1. Name of the medicinal product Antepsin 1g Tablets 2. Qualitative and quantitative composition Each tablet contains 1 gram of sucralfate. For the full list of excipients, see section 6.1. 3. Pharmaceutical form Tablet Biconvex, oblong, white tablets with a dividing score on one side. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4. Clinical particulars 4.1 Therapeutic indications Antepsin is indicated in adults and adolescents over 14 years old for treatment of duodenal ulcer, gastric ulcer, chronic gastritis. 4.2 Posology and method of administration For oral administration. _Duodenal ulcer, gastric ulcer, chronic gastritis:_ Adults_:_ The usual dose is 2 grams twice daily to be taken on rising and at bedtime, or 1 gram 4 times a day to be taken 1 hour before meals and at bedtime. Maximum daily dose: 8 grams. For ease of administration, Antepsin Tablets may be dispersed in 10-15 mL of water. Four to six weeks' treatment is usually needed for ulcer healing, but up to twelve weeks may be necessary in resistant cases. Antacids may be used as required for relief of pain, but should not be taken half an hour before or after Antepsin. Elderly_: _There are no special dosage requirements for elderly patients but, as with all medicines, the lowest effective dose should be used. Paediatric population_: _The safety and efficacy of Antepsin in children under 14 years of age has not been established. Currently available data are described in section 5.1 but no recommendation on posology can be made. 4.3 Contraindications Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 4.4 Special warnings and precautions for use The product should only be used with caution in patients with renal dysfunction, due to the possibility of increased aluminium absorption. Sucralfate is not recommended for use in individuals on dialysis. Soma hati kamili